InMed Pharmaceuticals (INM) EPS (Basic) Growth (3y) (2024 - 2026)
InMed Pharmaceuticals (INM) EPS (Basic) Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.00 Bn | 43.04 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | 15.17% |
| 3 | Zoetis | 31.78 Bn | 30.10 Bn | 1.05 Bn | 3.18% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.92 Bn | 5.10 Bn | 2.42% |
| 5 | United Therapeutics | 22.21 Bn | 19.54 Bn | 683.80 Mn | 12.25% |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | -35.06% |
| 7 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn | 13.47% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 36.60% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - | 60.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.68% |
| Dec 31, 2025 | 69.59% |
| Sep 30, 2025 | 82.47% |
| Jun 30, 2025 | 83.17% |
| Mar 31, 2025 | 92.63% |
| Dec 31, 2024 | 71.33% |
| Sep 30, 2024 | 72.01% |